Sisätautien yksikkö
Department of Internal Medicine

Julkaisut 2003
Publications 2003

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Conroy RM et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
2 Boersma E et al. Blood pressure is insufficiently controlled in European patients with esteblished coronary heart disease.
3 Chiasson J-L et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOPP-NIDDM Trial.
4 de BACKER G et al. European guidelines on cardiovascular disease prevention in clinical practice.
5 de Bacquer D et al. Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort.
6 De Sutter J et al. Screening of family members of patients with premature coronary heart disease .
7 Eriksson J et al. The effects of the Pro12Ala polymorphism of the PPARgamma-2 gene on lipid metabolism interact with body size at birth.
8 Eriksson JG et al. Interactions between peroxisome proliferator-activated receptor gene polymorphism and birth length influence risk for type 2 diabetes.
9 Erkkilä AT et al. n-3 fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease1-3.
10 Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfain in patients eith non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
11 Fueger PT et al. Hexokinase II partial knockout impairs exercise-stimulated glucose uptake in oxidative muscles of mice.
12 Goldstein S et al. Metoprolol CR/XL in blanck patients with heart failure (from the Metoprolol CR/XL randomized intervention Trial in chronic heart failure).
13 González-Sánchez JL et al. K121Q PC-1 gene polymorphism is not associated with insulin resistance in a Spanish population.
14 Haffner SM et al. Low insulin sensitivity (Si=O) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study.
15 Halinen M. Antikoagulaatiohoito sydämen vajaatoiminnassa.
16 Halperin JL et al. Ximelagatran compared with warfarin for prevention pf thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives,and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
17 Hedman M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II [...].
18 Heiskanen T et al. Metabolic syndrome in patients with schizophrenia.
19 Huopio H et al. A new subtype of autosomal dominant diabetes attributabe to a mutation in the gene for sulfonylurea receptor 1.
20 Hyttinen L et al. Recurrent myopericarditis in association with Crohn`s disease.
21 Häkkinen A et al. Effects of concurrent strength and endurance training in women with early or longstanding rheumatoid arthritis: comparison with healthy subjects.
22 Häkkinen A et al. Effects of dynamic strength training on physical function, valpar 9 work sample test, and working capacity in patients with recent-onset rheumatoid arthritis.
23 Ikonen AEJ et al. Three-dimensional respiratory-gated coronary MR angiography with reference to x-ray coronary angiography.
24 Jantunen E et al. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma.
25 Jantunen E et al. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
26 Jantunen E et al. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patient with non-Hodgkin`s lymphoma?
27 Jantunen E et al. Multiple complete remissions in a patient with acute myeloid leukemia (M4eo) with low-dose cytosine arabinoside and all-trans retinoic acid.
28 Jantunen E et al. Low-dose or intermediate-dose cyclophoshamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.
29 Jantunen E et al. Central nervous system aspergillosis in allogeneic stem cell transplant resipients.
30 Julkunen R. Alkoholihepatiitin hoito.
31 Juntunen KS et al. Structural differences between rye and wheat breads but not total fiber content may explain the lower postprandial insulin response to rye bread.
32 Juntunen KS et al. High-fiber rye bread and insulin secretion and sensitivity in healthy postmenopausal women 1-3.
33 Juntunen M et al. Changes in body weight and onset of hypertension in perimenopausal women.
34 Jánosi A et al. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: Experiences from MERIT-HF.
35 Kaipiainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alfa inhibitors.
36 Kaipiainen-Seppänen O et al. Treatment of reactive arthritis with infliximab.
37 Karikumpu A et al. Päivystyksen ylläpidon kustannukset yliopistosairaaloissa.
38 Kekäläinen P et al. A pitfall of metaiodobenzylguanidine scan: paraganglioma in close proximity to adrenocortical adenoma.
39 Kolehmainen M et al. Effect of the pro12ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects.
40 Korhonen S et al. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome.
41 Korhonen S et al. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study.
42 Korpilähde T et al. Regional differences in Finland in the prevalence of rheumatoid factor in the presence and absence of arthritis.
43 Kossila M et al. Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in Finnish subjects.
44 Krishnan E et al. Smoking-gender interaction and risk for rheumatoid arthritis.
45 Kubaszek A et al. The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia.
46 Kubaszek A et al. Promoter polymorphisms of the TNF-alfa (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study.
47 Kubaszek A et al. The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity .
48 Kusnetsov J et al. Colonization of hospital water systems by legionellae, mycobacteria and other heterotrophic bacteria potentially hazardous to risk group patients .
49 Kärkkäinen S et al. A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy.
50 Laakso M. Akarboosi - tehokas lääke tyypin 2 diabeteksen ja sydänsairauksien estoon?
51 Laakso M. Epidemiology and diagnosis of type 2 diabetes.
52 Laakso M, Huopio H. From hyperinsulinemia in childhood to diabetes in adulthood.
53 Laakso M, Kubaszek A. Coronary artery disease in type 2 diabetes.
54 Laakso M, Kubaszek A. Candidate genes for insulin resistance: what's new?
55 Laakso M, Kuusisto J. Understanding patient needs. Diabetology for cardiologists.
56 Laaksonen DE et al. Relationships between changes in abdominal fat distribution and insulin sensitivity during a very low calorie diet in abdominally obese menand women.
57 Laaksonen DE et al. Weight loss and weight maintenance, ambulatory blood pressure and cardiac autonomic tone in obese persons with the metabolic syndrome.
58 Laaksonen DE et al. Cardiorespiratory fitness and vigorous leisure-time physical activity modify the association of small size at birth with the metabolic syndrome.
59 Laaksonen DE et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study.
60 Laaksonen DE et al. Changes in abdominal subcutaneous fat water content with rapid weight loss and long-term weight maintenance in abdominally obese men and women.
61 Laitinen T et al. Effects of euglycaemic and hypoglycaemic hyperinsulinaemia on sympathetic and parasympathetic regulation of haemodynamics in healthy subjects.
62 Laitinen T et al. Prolonged corrected QT interval is associated with acute and chronic hyperinsulinemia in nondiabetic subjects.
63 Lakka TA et al. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome.
64 Lindi V et al. Impact of the pro12ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n - 3 fatty acid supplementation. For the KANWU study group.
65 Lumiaho A. Genetic Background and Phenotype of Autosomal Dominant Polystic Kidney Disease in Eastern Finland.
66 Lumiaho A et al. Progression of kidney disease varies between families with defects in the polycystic kidney disease type 1 gene in eastern Finland.
67 Lumiaho A et al. Insulin resistance is related to left ventricular hyperthrophy in patients with polycystic kidney disease type 1.
68 Luosujärvi RA et al. Joint symptoms and diseases associated with moisture damage in a health center.
69 Mussalo H. Cardiovascular Autonomic Regulation in Patients with Sustained Hypertension of Different Etiology and Severity.
70 Mussalo H et al. NT-proANP and BNP in renovascular and in severe and mild essential hypertension.
71 Mussalo H et al. Short-term blood pressure variability in renovascular hypertension and in severe and mild essential hypertension.
72 Neva MH et al. Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis.
73 Newby LK et al. Predictors of 90-day outcome in patients stabilized after acute coronary syndromes.
74 Niskanen L et al. Association of the PRO12ALA polymorphism of the PPAR-gamma2 gene with oxidized low-density lipoprotein and cardiolipin autoantibodies in nondiabetic and type 2 diabetic subjects.
75 Niskanen L et al. Reply (to the editor).
76 Oksala N et al. Ulkustaudin epidemiologia tänään Kirurgisen hoidon ilmaantuvuus, sairaalahoitojaksot sekä kuolleisuusluvut Suomessa.
77 On behalf of the MERIT-HF Study Group et al. An evaluation of the beta-1 adrenergic receptor arg389gly polymorphism in individuals with heart failure: a merit-hf sub-study.
78 Pajukanta P et al. Combined analysis of genome scans of Dutch and Finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q.
79 Papp A et al. Myocardial function and haemodynamics in extensive burn trauma: evaluation by clinical signs, invasive monitoring, echocardiography and cytokine concentrations. A prospective clinical study.
80 Penttilä HJ et al. Ischemic preconditioning does not improve myocardial preservation during off-pump multivessel coronary operation.
81 Petersen P et al. Ximelagatran versus Warfarin for stroke Prevention patients with nonvalvular atrial fibrillation.
82 Pihlajamäki J et al. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism .
83 Pihlajamäki J et al. The effect of the -308A allele of the TNF-alfa gene on insulin action is dependent on obesity.
84 Puhakka M et al. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation.
85 Pyörälä M. Hyperinsulinaemia and the Risk of Cardiovascular Disease. The 22 -Year Follow-up Results of the Helsinki Policemen Study.
86 Reimann F et al. Characterisation of new KATP-channel mutations associated with congenital hyperinsulinism in the Finnish population.
87 Salomaa V et al. Decline in out-of-hospital coronary heart disease deaths has contributed the main part to the overall decline in coronary heart disease mortality rates among persons 35 to 64 years of age in Finland.
88 Salomaa V et al. Trends in coronary events in Finland during 1983-1997; the FINAMI study.
89 Saraheimo M et al. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients.
90 Savolainen E et al. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey.
91 Sipola P et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the asp 175asn mutation of the alfa-tropomyosin gene.
92 Sipola P et al. Cardiac adrenergic activity is associated with left ventricular hypertrophy in genetically homogenous subjects with hypertrophic cardiomyopathy.
93 Sivenius K et al. A deletion in the alfa2B-adrenergic receptor gene and autonomic nervous function in central obesity.
94 Soinio M et al. Dietary fat predicts coronary heart disease events in subjects with type 2 diabets.
95 Sokka T et al. Erosions develop rarely in joints without clinically detectable inflammation in patients with early rheumatoid arthritis.
96 Sokka T et al. Functional disability in rheumatoid arthritis patients compared with a community population in Finland.
97 Suistomaa M. Clinical Course and Outcome in Intensive Care. Methodological aspects with special reference to early circulatory failure.
98 Suomen Kardiologisen Seuran asettama työryhmä. Sepelvaltimotautikohtaus: epästabiili angina pectoris ja sydäninfarkti ilman ST-nousuja - vaaran arviointi ja hoito.
99 Tarkiainen TH et al. Effect of acute carbon monoxine exposure on heart rate variability in patients with coronary artery disease.
100 The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases.
101 Tolleson TR et al. Frequency of stent thrombosis after acute coronary syndromes (from the symphony and 2nd symphony trials).
102 Udd M et al. Effect of short-term treatment with regular or high doses of omeprazole on the detection of helicobacter pylori in bleeding peptic ulcer patients.
103 Valkamo M. Rintakivun psyykkiset ulottuvuudet.
104 Valkamo M et al. Life satisfaction in patients with chest pain subsequently diagnosed as coronary heart disease-connection through depressive symptoms?
105 Viik-Kajander M et al. Geographical variation in the incidence of acute myocardial infarction in eastern Finland-a Bayesian perspective.
106 Vikman S et al. Sepelvaltimotautikohtauksen hoito Suomessa.
107 Vikman S et al. Gap between guidelines and management of patients with acute coronary syndrome without persistent ST elevation. Finnish prospective follow-up survey.
108 Vikman S et al. Underuse of evidence-based treatment modalities in diabetic patients with non-ST elevation acute coronary syndrome. A prospective nation widw study on acute coronary syndrome (FINACS).
109 Vuorela J et al. Does yttrium radiosynovectomy increase the risk of cancer in patients with rheumatoid arthritis.
110 Vuotikka P et al. Serum myoglobin/carbonic anhydrase III ratio as a marker of reperfusion after myocardial infarction.
111 Wallentin L et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.

Sisätautien yksikkö Department of Internal Medicine
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008